Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Marinus Pharmaceuticals, Inc. - Common Stock
(NQ:
MRNS
)
0.5500
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Marinus Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
September 27, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 30, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates OMIC, MRNS, VCSA on Behalf of Shareholders
January 07, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
January 06, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MoneyLion Inc. (NYSE - ML), Marinus Pharmaceuticals, Inc. (Nasdaq - MRNS), Better Choice Inc. (NYSE American - BTTR), NeueHealth, Inc. (NYSE - NEUE)
January 03, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders
December 31, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
December 30, 2024
Via
Benzinga
Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%
↗
December 30, 2024
Immedica Pharma AB to acquire Marinus Pharmaceuticals, Inc. for $151 million, giving them control of ZTALMY and expanding their global presence.
Via
Benzinga
Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
December 30, 2024
From
Ademi LLP
Via
Business Wire
MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
December 30, 2024
From
Halper Sadeh LLC
Via
Business Wire
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
December 30, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
November 12, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
October 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
October 28, 2024
Via
Benzinga
Crude Oil Down 1%; Dow Posts Upbeat Earnings
↗
October 24, 2024
Via
Benzinga
Topics
Stocks
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
↗
October 24, 2024
Marinus Pharmaceuticals stock plummeted after disappointing data from the Phase 3 TrustTSC trial of ganaxolone for seizures linked to tuberous sclerosis complex.
Via
Benzinga
Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results
↗
October 24, 2024
Via
Benzinga
Dow Falls 150 Points; Tesla Posts Upbeat Earnings
↗
October 24, 2024
Via
Benzinga
Topics
Stocks
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
October 24, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
October 17, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
October 15, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
October 11, 2024
Check out these three micro-cap stocks that show big-time potential upside, but also pose face large obstacles to achieving success.
Via
MarketBeat
Topics
ETFs
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
October 09, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 08, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
October 01, 2024
Marinus is an under $2 biotech stock with Wall Street analysts price targets ranging from $2 to $13. Its upcoming trial results have big implications.
Via
MarketBeat
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
September 20, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
September 12, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
August 19, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024
↗
August 13, 2024
MRNS stock results show that Marinus Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
